Updated
Intellia TherapeuticsNTLA · Healthcare
$11.35+2.25%
Market cap$1.6B
IndustryBiotechnology

Intellia Therapeutics (NTLA) Superinvestor holders

14 of the superinvestors we track hold Intellia Therapeutics (NTLA) in their latest 13F filings, $619M in total.

Summary

The largest holder is Cathie Wood (ARK Investment Management), with $286M, 1.9% of the portfolio.

In their latest quarter: 1 opened a new position, 10 added, 3 trimmed.

Who holds it

Each investor's latest 13F filing, largest stake first. What a 13F shows.

InvestorLast changeSharesValue% of portfolioFiled for
Cathie Wood
ARK Investment Management
Added 16,875,684$286M 1.9%Q2 2026
David Shaw
D. E. Shaw & Co.
Added 6,443,323$109M 0.1%Q2 2026
Two Sigma
Two Sigma Investments
Added 5,235,348$89M 0.1%Q2 2026
Arrowstreet Capital Added 3,280,760$56M 0.0%Q2 2026
David Vogel
Voloridge Investment Management
Added 2,066,356$35M 0.1%Q2 2026
Jim Simons
Renaissance Technologies
New position 1,400,004$24M 0.0%Q2 2026
Cliff Asness
AQR Capital Management
Trimmed 492,954$8M 0.0%Q2 2026
Steve Cohen
Point72 Asset Management
Added 398,463$7M 0.0%Q2 2026
Paul Marshall
Marshall Wace
Added 164,078$3M 0.0%Q2 2026
Paul Tudor Jones
Tudor Investment Corp
Added 116,908$2M 0.0%Q2 2026
Alan Howard
Brevan Howard
Added 77,951$1M 0.0%Q2 2026
Peter Muller
PDT Partners
Trimmed 37,076$627,326 0.0%Q2 2026
Murray Stahl
Horizon Kinetics LLC
Trimmed 12,584$212,921 0.0%Q2 2026
Ensign Peak
Ensign Peak Advisors
Added 9,569$161,907 0.0%Q2 2026

Holders by quarter

QuarterSuperinvestors holding it
Q2 202615
Q1 202616
Q4 202515
Q3 202514
Q2 202512
Q1 20259
Q4 202411
Q3 202411

Questions about Intellia Therapeutics

Which superinvestors own Intellia Therapeutics?

14 of the superinvestors we track hold Intellia Therapeutics (NTLA) in their latest 13F filings, $619M in total. Cathie Wood, David Shaw, Two Sigma, Arrowstreet Capital, David Vogel, Jim Simons.

Who is the largest superinvestor holder of NTLA?

The largest holder is Cathie Wood (ARK Investment Management), with $286M, 1.9% of the portfolio.

From Intellia Therapeutics's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.

Investingly

Better research starts here.

Every filing, chart and insider trade behind Intellia Therapeutics and thousands of other companies, in one place. Free to start.